TNBC accounts for 10–20% of all breast cancer subtypes [5], and its resistance to endocrine and HER2-targeted therapies necessitates extensive exploration of its unique characteristics compared to other breast cancer subtypes [6]. This evidence concerns the gene ERBB2 and breast carcinoma.